Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance.
Approximately 25% of patients with Fanconi anemia (FA) have evidence of spontaneously occurring mosaicism as manifest by the presence of two subpopulations of lymphocytes, one of which is hypersensitive to cross-linking agents (e.g. mitomycin C) while the other behaves normally in response to these agents. The molecular basis of this phenotypic reversion has not yet been determined. We have investigated 8 FA patients with evidence of mosaicism. Epstein-Barr virus-immortalized lymphoblastoid cell lines established from these patients exhibited an IC50 for mitomycin C of 25 to > 100 nM compared to a mean of 2 +/- 2 nM for 20 nonmosaic FA patients and 49 +/- 11 nM for 8 healthy controls. In 3 patients who were compound heterozygotes for pathogenic FAC gene mutations the molecular mechanism of the mosaicism was investigated by haplotype analysis. The results indicated that an intragenic mitotic recombination must have occurred leading to a segregation of a wild-type allele in the reverted cells and suggested two patterns of recombination. In 1 patient a single intragenic crossover between the maternally and paternally inherited mutations occurred associated with markers located distally to the FAC gene; in the other 2 patients (sibs) the mechanism appears to have been gene conversion resulting in segregants which have lost one pathogenic mutation. In 6 of the 8 patients the hematological symptoms were relatively mild despite an age range of 9-30 years.
Lo Ten Foe
J R
JR
Department of Human Genetics, Free University, Amsterdam, The Netherlands.
Kwee
M L
ML
Rooimans
M A
MA
Oostra
A B
AB
Veerman
A J
AJ
van Weel
M
M
Pauli
R M
RM
Shahidi
N T
NT
Dokal
I
I
Roberts
I
I
Altay
C
C
Gluckman
E
E
Gibson
R A
RA
Mathew
C G
CG
Arwert
F
F
Joenje
H
H
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D002478:Cells, Cultured; D002648:Child; D019457:Chromosome Breakage; D003432:Cross-Linking Reagents / Q000494:pharmacology; D004252:DNA Mutational Analysis; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005091:Exons; D005199:Fanconi Anemia / Q000235:genetics* / Q000276:immunology; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000648:ultrastructure; D005785:Gene Conversion; D006239:Haplotypes; D006412:Hematopoietic Stem Cells / Q000502:physiology; D004854:Herpesvirus 4, Human; D006579:Heterozygote; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D008297:Male; D018895:Microsatellite Repeats; D016685:Mitomycin / Q000494:pharmacology; D009030:Mosaicism / Q000175:diagnosis / Q000235:genetics* / Q000276:immunology; D010641:Phenotype; D011110:Polymorphism, Genetic
D000903:Antibiotics, Antineoplastic; D003432:Cross-Linking Reagents; D016685:Mitomycin